Drugs / GVXN SD133
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01069471 | Feb → Oct 2010 | shigellosis | GlycoVaxyn AG | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GVXN SD133 | “A novel S. dysenteriae bioconjugate vaccine (GVXN SD133) made of the polysaccharide component of the Shigella O1 lipopolysaccharide, conjugated to the exotoxin protein A of...” PMID 26162850 ↗ Jul 2015 |
| Modality | Vaccine | “A novel S. dysenteriae bioconjugate vaccine (GVXN SD133)” PMID 26162850 ↗ Jul 2015 |
| Route | Intramuscular | “Two intramuscular injections of bioconjugate vaccine will be administrated at D0 and D60.” NCT01069471 ↗ |